[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"morality\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:morality":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,45,79,108,137,166,191,220,244],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100333973","valvular-aortic-stenosis-prognosis-study-100333973",false,"NCT03628313","Valvular Aortic Stenosis Prognosis Study","Valvular Aortic Stenosis Prognosis Study: Prospective and Retrospective Follow-up of a Cohort of Patients With Aortic Valve Narrowing","EPRAoV","Inclusion Criteria:\n\n* Retrospectively, all patients examined from January 1, 2000 to November 2014 will be included in the echocardiography laboratory whose objective examination is a narrowing of the aortic valve (maximum transaortic velocity ≥2.5 m \u002F s).\n* Aortic stenosis may be known in the past.\n\nExclusion Criteria:\n\n* Refusal of the patient to participate in the study.\n* Patients who have previously had aortic valve surgery before being examined in the echocardiography laboratory.\n* Patients who can not be contacted or who do not respond will not be included in the database.","ALL","18 Years","100 Years",{"count":21,"type":22},3450,"ESTIMATED","OBSERVATIONAL","Aortic stenosis is the most common valvulopathy in Western countries. Cardiac EchoDoppler is the reference method for assessment of aortic stenosis and provides prognostic elements. However, it is imperfect with many inconsistencies between measures. On the other hand, the prognosis of patients with low flow and low gradient aortic retraction is discussed.\n\nThe main objective of this work is to study the prognosis of asymptomatic and symptomatic aortic retraction.",[26],"Morality",[28,29,30,31],"Echoacrdiography","EchoDoppler","Aortic valve stenosis","Prognosis","RECRUITING","2026-06-23",{"date":35,"type":36},"2026-06-25","ACTUAL",{"date":38,"type":36},"2015-09-03",{"date":40,"type":22},"2026-06",{"name":42,"class":43},"Centre Hospitalier Universitaire, Amiens","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":55,"phases":56,"briefSummary":58,"conditions":59,"keywords":63,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":4},"100638342","mechanical-power-for-ventilatory-settings-in-operating-room-100638342","NCT07620132","Mechanical Power for Ventilatory Settings in Operating Room","Mechanical Power for Ventilatory Settings in Operating Room: a Multicenter Randomized Controlled Trial","IMPROVEIII","Inclusion Criteria:\n\n* Adult (≥ 18 years)\n* Laparoscopic or non-laparoscopic abdominal surgery\n* With an expected duration of at least 2 hours\n\nExclusion Criteria:\n\n* Patients already receiving mechanical ventilation \\> 12 hours before surgery;\n* Chronic respiratory disease requiring oxygen therapy or mechanical ventilation at home;\n* Undrained pneumothorax or subcutaneous emphysema;\n* Intracranial hypertension;\n* Patients for which death is deemed imminent and inevitable or patients with an underlying disease process with a life expectancy of less than 3 months;\n* Patients already enrolled in the IMPROVE III trial;\n* Pregnancy in progress or planned during the study period or breastfeeding women (Art. L1121-5 of the French Public Health Code);\n* Patients protected by law (Art. L1121-6 to L1121-8 of the French Public Health Code): Individuals deprived of their liberty by judicial or administrative decision, vulnerable persons, minors, adults under guardianship or curatorship;\n* Patients not covered by a French social security scheme and not benefiting from such a scheme;\n* Absence of free and informed oral consent from the patient before inclusion (except in emergency situation where the patient is unable to provide consent), or absence of written informed consent from his\u002Fher proxy if present in an emergency situation (except in life-threatening emergency, where inclusion without consent from the patient or his\u002Fher proxy is permitted), in which case consent will be obtained as soon as possible after inclusion.",{"count":54,"type":22},490,"INTERVENTIONAL",[57],"NA","Postoperative respiratory failure (PRF) is a dreaded complication that imposes a significant burden through unplanned admission to the ICU, post discharge disability and mortality. Despite widespread implementation of intraoperative lung-protective ventilation strategies over the past decade, results remain inconsistent. Interventions targeting individual parameters like tidal volume or positive end-expiratory pressure (PEEP) have shown equivocal results. The use of high PEEP and recruitment maneuvers raises safety concerns by possible negative hemodynamic effects. Recent studies suggest that individualizing ventilation strategies based on mechanical power-a composite parameter integrating tidal volume, plateau pressure, PEEP, and ventilator frequency-may better predict and help prevent PRF, independently of patients' baseline respiratory system compliance. These studies identified this parameter as interventional targets to reduce lung injury during mechanical ventilation. However, no multicenter randomized controlled trial has been performed in the field of ventilatory settings titration during invasive mechanical ventilation in operating room.\n\nThe investigators hypothesize that a ventilation strategy aimed at decreasing mechanical power will reduce the incidence of PRF and mortality in patients undergoing abdominal surgery, compared with a standard strategy using fixed tidal volume and PEEP",[60,61,62,26],"Postoperative Respiratory Failure","Abdominal Surgery","Postoperative Pulmonary Complications",[64,65,66,67,68],"Mechanical ventilation","Intubation","Mechanical power-guided ventilation","Laparoscopic or non-laparoscopic abdominal surgery","Intensive care unit","NOT_YET_RECRUITING","2026-05-26",{"date":72,"type":36},"2026-06-02",{"date":74,"type":22},"2026-06-01",{"date":76,"type":22},"2029-01-01",{"name":78,"class":43},"University Hospital, Montpellier",{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":85,"eligibilityCriteria":86,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":87,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":88,"conditions":89,"keywords":92,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":107},"100529110","health-systems-and-policy-contexts-of-medical-oxygen-100529110","NCT06169514","Health Systems and Policy Contexts of Medical Oxygen","Understanding the Health Systems and Policy Contexts of Medical Oxygen in Africa and Asia (MOXY-HSP)","MOXY-HSP","Key informants will be selected representing government, non-governmental agencies, professional associations, private sector, and civil society.",{"count":44,"type":22},"This is a mixed-methods program evaluation from a health systems and policy perspective, involving (i) stakeholder analysis, (ii) policy-implementation gap analysis, and (iii) comparative country case studies. This study aims to understand how national oxygen strategies achieve impact at national, and subnational level, across country contexts, at what cost.\n\nThe the investigators seek to:\n\n1. Involve policymakers, implementers (including private sector), and medical oxygen users in identifying challenges and understanding potential solutions to medical oxygen access;\n2. Generate new data on how medical oxygen systems work and can be improved from multiple perspectives;\n3. Draw lessons on medical oxygen that can directly inform national and global practice and policy.\n\nThis study will be conducted in 6 of the 9 countries participating in the Clinton Health Access Initiative (CHAI) led Medical Oxygen Implementation (MOXY) program (Uganda, Nigeria, Rwanda, Liberia, Lao PDR, Cambodia).\n\nKey informants will be selected representing government, non-governmental agencies, professional associations, private sector, and civil society. This study will be completed over 4 years, with timelines varying between country study sites.",[90,26,91],"Hypoxemia","Pneumonia",[93,94,95,96,97],"Health system","Oxygen","Oxygen systems","Oxygen access","Pulse oximetry","2026-02-04",{"date":100,"type":36},"2026-02-06",{"date":102,"type":36},"2024-07-31",{"date":104,"type":22},"2027-12",{"name":106,"class":43},"Murdoch Childrens Research Institute",6,{"id":109,"slug":110,"hasResults":11,"nctId":111,"briefTitle":112,"officialTitle":113,"acronym":4,"eligibilityCriteria":114,"healthyVolunteers":115,"sex":17,"minAge":116,"maxAge":4,"enrollmentInfo":117,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":119,"conditions":120,"keywords":122,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":126,"lastUpdatePostDateStruct":127,"startDateStruct":129,"completionDateStruct":131,"leadSponsor":133,"locationsCount":136},"100593700","an-observational-study-to-assess-effectiveness-and-safety-of-the-r21matrix-m-malaria-vaccine-100593700","NCT07009847","An Observational Study to Assess Effectiveness and Safety of The R21\u002FMatrix-M Malaria Vaccine","A Case Control Study to Assess Effectiveness and Safety of The R21\u002FMatrix-M Malaria Vaccine","Inclusion Criteria:\n\nFor Cases- A male or female child eligible to have received R21\u002FMatrix-M Vaccine based on age. 2 Parent\u002Flegal guardian\u002F caregiver of the child willing to provide the written informed consent for their child's participation in the study.\n\n3 Parent\u002Flegal guardian\u002F caregiver willing to comply with the study requirements and share or allow access to the data regarding the vaccination status and medical records with the study personnel.\n\n4 Resident of the R21\u002FMatrix-M vaccine implementation area and brought to the study hospital \u002Fclinic or sub-site with clinical complaints. 5 Child meeting the respective case definition (Severe Malaria, Clinical Malaria or Death due to any cause).\n\nFor Controls- A male or female child eligible to have received R21\u002FMatrix-M Vaccine based on age. The matched control should have a date of birth within 60 days of that of the case.\n\n2\\. Parent\u002Flegal guardian\u002F caregiver of the child willing to provide the informed consent for their child's participation in the study.\n\n3\\. Parent\u002F legal guardian\u002F caregiver willing to comply with the study requirements and share or allow access to the data regarding the vaccination status and medical records with the study personnel 4. Resident of the R21\u002FMatrix-M vaccine implementation area and who would have sought treatment at the same hospital if they had developed symptoms. Resident will be defined as child and\u002For child's parents\u002F guardian\u002Fcaregiver eating and sleeping in a household in the location for most days of the week from past 6 months. The matched control should be residing in the same neighborhood as the respective case, but not from the same household.\n\nExclusion Criteria:\n\nFor Cases-\n\n1. Parent\u002Flegal guardian\u002F caregiver not consenting to let the child participate or not permitting to access the data related to vaccination or other medical records.\n2. Child not meeting the respective case definition (Severe Malaria, Clinical Malaria or Death due to any cause).\n3. Received one or more doses of RTS,S\u002FAS01 vaccine in the past.\n\nFor Controls-\n\n1. Parent\u002Flegal guardian\u002F caregiver not consenting to let the child participate or not permitting to access the data related to vaccination or other medical records.\n2. Child meeting any of the case definitions (Severe Malaria, Clinical Malaria).\n3. Child having history suggestive of clinical malaria in past 30 days (applicable for clinical malaria and severe malaria case-control studies only).\n4. Received one or more doses of RTS,S\u002FAS01 vaccine\u002Fs in the past.",true,"5 Months",{"count":118,"type":22},2308,"This is an observational case-control study to assess the effectiveness of the R21\u002FMatrix-M vaccine against severe malaria, clinical malaria (in high transmission perennial areas), and to assess if the R21 vaccine recipients are at an increased risk of deaths (all-cause). Clinical malaria, severe malaria and death (all-cause) cases will be enrolled in study. For each case (severe or death) 4 controls matched for age and neighborhood will be enrolled whereas for clinical malaria case, 1 matched control will be enrolled.\n\n1. Proportion of vaccinated and unvaccinated children amongst Severe Malaria Cases caused by P. falciparum.\n2. Proportion of vaccinated and unvaccinated children amongst Clinical Malaria Cases in high-transmission perennial areas caused by P. falciparum.\n3. Proportion of vaccinated and unvaccinated children in cases of death (all cause)\n4. Exploratory effectiveness endpoint: Proportion of vaccinated and unvaccinated children in the hospitalized clinical and severe malaria cases.",[121,26],"Malaria,Falciparum",[123,124,125],"clinical malaria","severe malaria","death (all cause)","2025-08-12",{"date":128,"type":36},"2025-08-13",{"date":130,"type":36},"2025-06-16",{"date":132,"type":22},"2026-12-31",{"name":134,"class":135},"Serum Institute of India Pvt. Ltd.","INDUSTRY",5,{"id":138,"slug":139,"hasResults":11,"nctId":140,"briefTitle":141,"officialTitle":142,"acronym":143,"eligibilityCriteria":144,"healthyVolunteers":11,"sex":17,"minAge":145,"maxAge":146,"enrollmentInfo":147,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":149,"conditions":150,"keywords":153,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":158,"lastUpdatePostDateStruct":159,"startDateStruct":161,"completionDateStruct":163,"leadSponsor":164,"locationsCount":165},"100522799","evaluation-of-a-multi-country-medical-oxygen-program-100522799","NCT06087315","Evaluation of a Multi-country Medical Oxygen Program","Realist Evaluation and Learning in a Multi-country Medical OXYgen Program (REAL-MOXY)","REAL-MOXY","Sub-study 1:\n\nResearch Question: What are the baseline pulse oximetry and oxygen practices for children admitted to participating health facilities, and what is the level of institutional readiness for oxygen service delivery? Which facilities, representative of high- and low-performing facilities and different levels of care and facility types, can be selected for additional investigation to understand current functioning of oxygen systems?\n\nSetting and Population: The broader MOXY program baseline cross-sectional assessments involve 9 countries. We have selected 6 MOXY countries for the mixed methods studies outlined in this protocol - Nigeria, Uganda, Liberia, Rwanda, Cambodia and Lao PDR - based on pre-existing research collaborations, and with the aim of representing broadly different geographical contexts.\n\nBaseline assessments are being conducted in all facilities participating in the MOXY program in each of the 6 study countries. From this data set, we will analyse primary and secondary outcomes for wards caring for children \\\u003C15 years (including neonatal wards where relevant).\n\nAnalysis\u002Foutcomes: Primary - proportion of admitted children (\\\u003C15 years, including neonates) screened with pulse oximetry. Secondary - proportion of admitted children with hypoxaemia (\\\u003C15 years, including neonates) treated with oxygen. For Real-Moxy the secondary outcome will inform identification of facilities for inclusion.\n\nSub-study 2:\n\nResearch question: Where and how are patients managed from arrival to admission and discharge (or transfer), and how does oxygen equipment move within and between clinical areas? How do process maps vary for different clinical scenarios representing different patient groups: i) pneumonia with and without hypoxaemia; ii) severe, acute illness syndrome with WHO emergency signs (e.g., shock, multi-trauma, seizures); iii) surgical condition and iv) neonatal illness (inborn and outborn)?\n\nSetting and Population: This will be conducted in 10 health facilities in each of the 6 countries (Nigeria, Uganda, Liberia, Rwanda, Lao PDR, Cambodia), selected to represent high and low functioning facility oxygen systems and include secondary and tertiary health facilities from government and non-governmental sectors (identified in sub-study 1). We will focus on admitted children (\\\u003C15 years, including neonates) with (i) pneumonia, (ii) other acute illness with WHO emergency signs, (iii) surgical conditions, and (iv) neonatal illness. We have chosen these conditions to represent diagnoses with a high prevalence of hypoxaemia, and to capture the nuances of how pulse oximetry and oxygen practices are adapted (or not adapted) to clinical scenarios (e.g., having a lower threshold to provide oxygen to a patient in shock; or targeting safe oxygen saturations in neonates).\n\nAnalysis\u002Foutcomes: Facility maps of patient and equipment flow.\n\nSub-study 3:\n\nResearch question: What is the sequence of emergency care for an unwell child in the first 4 hours, and how are decisions made - particularly relating to oxygen (when to start, stop, how much, what delivery modality, etc.)? What are the points of delays to appropriate care (including pulse oximetry and oxygen) and at what points in time and location could pulse oximetry and oxygen be used better for emergency care of children?\n\nSetting and Population: facilities are same as sub-study 2). Children (\\\u003C15 years, including neonates) presenting with each of 4 acute illness syndromes: (i) pneumonia, (ii) other acute illness with WHO emergency signs, (iii) surgical conditions, and (iv) neonatal illness.\n\nAnalysis\u002Foutcomes: Patient journey maps.\n\nSub-study 4:\n\nResearch question: How do healthcare workers use pulse oximetry and oxygen for admitted patients, and how does this change over time and vary between patient groups, facility type, and location? How do practices compare with treatment guidelines and where are the priority areas for improving oxygen care?\n\nPopulation and setting: Facilities are same as sub-studies 2\\&3.\n\nAnalysis\u002Foutcomes: Narrative descriptions of handover, ward rounds, and nursing rounds, with specific emphasis on how pulse oximetry is used, and decision making for oxygen therapy.\n\nSub-study 5: Indepth interviews and focus group discussions Research questions: 5a) How do patients\u002Fcaregivers perceive pulse oximetry and oxygen therapy within their broader care experience? 5b) How do healthcare workers, managers and technicians perceive oxygen therapy and the provision of oxygen-related care within the broader care provision experience?\n\nPopulation:\n\n* Patients and caregivers enrolled in sub-study 3 (patient journey mapping).\n* Healthcare workers (bedside), managers (including clinical and non-clinical managers) and technicians in each health facility. We will select staff with direct responsibility for wards caring for children \\\u003C15 years.\n\nAnalysis\u002Foutcomes: Reflexive thematic analysis of interviews and focus group discussions.","0 Years","15 Years",{"count":148,"type":22},1200,"REAL-MOXY is a set of 5 mixed methods studies designed to understand how oxygen and pulse oximetry are used (or not used) at a facility level, to identify opportunities and barriers for strengthening oxygen systems for beneficiaries, users and managers.",[90,151,91,152,26],"Neonatal Disease","Sepsis",[95,97,154,155,156,157],"Low middle income countries","Global health","Mixed-methods evaluation","Realist evaluation","2025-06-11",{"date":160,"type":36},"2025-06-15",{"date":162,"type":36},"2023-11-27",{"date":104,"type":22},{"name":106,"class":43},3,{"id":167,"slug":168,"hasResults":11,"nctId":169,"briefTitle":170,"officialTitle":170,"acronym":4,"eligibilityCriteria":171,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":172,"targetDuration":174,"studyType":23,"phases":4,"briefSummary":175,"conditions":176,"keywords":179,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":182,"lastUpdatePostDateStruct":183,"startDateStruct":185,"completionDateStruct":187,"leadSponsor":189,"locationsCount":44},"100548398","the-causal-effect-of-bariatric-surgery-on-cardiovascular-disease-and-mortality-100548398","NCT06420479","The Causal Effect of Bariatric Surgery on Cardiovascular Disease and Mortality","Inclusion Criteria:\n\n* Men and women of reproductive age with a diagnosis of obesity, no prior history of cardiovascular disease or cancer, and no contraindications for surgery after 1982\n\nExclusion Criteria:\n\n* Contraindications to bariatric surgery",{"count":173,"type":22},100000,"20 Years","The association between weight, and cardiovascular disease and mortality is well established, however, the causal effect of weight-loss in midlife on these outcomes is less clear. Bariatric surgery results in substantial weight-loss and is an ideal candidate to study the causal effects of weight-loss. The investigators propose a project that will use causal inference and machine learning methods to answer two important questions:\n\n1. Is bariatric surgery effective for reducing cardiovascular disease and mortality, and if so, for who?\n2. Which type of bariatric surgery (gastric bypass or sleeve gastrectomy) is most effective, and for who? The investigators will use data from various Swedish registers to identify individuals with obesity who are eligible for bariatric surgery. We will then compare cardiovascular and mortality outcomes among those undergoing different types of bariatric surgery with those receiving non-surgical obesity management using causal inference methods. The investigators will use causal forests and expert knowledge to estimate indiviual treatment effects, and identify the groups of patients who benefit the most from these surgeries.",[177,178,26],"Bariatric Surgery Candidate","Cardiovascular Diseases",[180,178,181],"bariatric surgery","Mortality","2024-06-13",{"date":184,"type":36},"2024-06-17",{"date":186,"type":36},"2024-01-01",{"date":188,"type":22},"2027-12-31",{"name":190,"class":43},"Karolinska Institutet",{"id":192,"slug":193,"hasResults":11,"nctId":194,"briefTitle":195,"officialTitle":195,"acronym":4,"eligibilityCriteria":196,"healthyVolunteers":11,"sex":17,"minAge":174,"maxAge":4,"enrollmentInfo":197,"targetDuration":4,"studyType":55,"phases":199,"briefSummary":200,"conditions":201,"keywords":206,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":211,"lastUpdatePostDateStruct":212,"startDateStruct":214,"completionDateStruct":216,"leadSponsor":218,"locationsCount":44},"100550891","the-impact-and-effect-of-traditional-chinese-medicine-treatment-on-organ-failure-in-critically-ill-patients-100550891","NCT06452966","The Impact and Effect of Traditional Chinese Medicine Treatment on Organ Failure in Critically Ill Patients","Inclusion Criteria:\n\n* Age 20 and above\n* Surgical ICU patients\n* The use of Chinese medicine must be approved by the attending physician in the surgical intensive care unit\n\nExclusion criteria:\n\n* Patients' family members refuse TCM intervention",{"count":198,"type":22},350,[57],"Critically ill patients are at risk of or suffering from one or more key organs or organ system failure. This study will measure the effect of traditional Chinese medicine(TCM) interventions on critically ill patients admitted to the intensive care unit (ICU).\n\nThe goal of this clinical trial is to learn if traditional Chinese medicine(TCM) is effective for prevention and treatment of organ failure in ICU patients. Patients in this group will receive intervention for 2 weeks.\n\nA multi-center non-randomized real word data study, will include 3 groups: intervention group (TCM)(n=70), control group and historical control group (admitted to the same ICU in the period of 01.2019 to 12.2023).\n\nMain outcomes include sequential organ failure assessment (SOFA) score, ICU length of stay, hospital length of stay, number of days of respirator uses and western medicine medication used study follow up will be 2 weeks.",[202,203,204,205,26],"Organ Failure, Multiple","Indigestion","Delayed Gastric Emptying","Respiratory Failure",[207,208,209,210],"acupuncture","chinese medicine","Organ Failure","intensive care","2024-06-06",{"date":213,"type":36},"2024-06-11",{"date":215,"type":36},"2024-05-07",{"date":217,"type":22},"2027-05-30",{"name":219,"class":43},"China Medical University Hospital",{"id":221,"slug":222,"hasResults":11,"nctId":223,"briefTitle":224,"officialTitle":225,"acronym":4,"eligibilityCriteria":226,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":227,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":229,"conditions":230,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":235,"lastUpdatePostDateStruct":236,"startDateStruct":238,"completionDateStruct":240,"leadSponsor":242,"locationsCount":44},"100484250","registry-for-hypoparathyroidism-wuerzburg-100484250","NCT05585593","Registry for Hypoparathyroidism Wuerzburg","Registry and Biobank for Patients With Hypoparathyroidism Wuerzburg","Inclusion Criteria:\n\n* age of 18\n* chronic hypoparathyroidism (\\>12 months) under established therapy or chronic pseudohypoparathyroidism (\\>12 months) under established therapy\n* written informed consent\n\nExclusion Criteria:\n\n* age \\\u003C18 years\n* no detailed documentation of hypo- or pseudohypoparathyroidism",{"count":228,"type":22},300,"Long-term conventional treatment of chronic hypoparathyroidism does not fully restore calcium homeostasis leading to increased morbidity, emergency events and reduced subjective health status. To further investigate general morbidity, hypocalcemic events, subjective and daily life performance in patients with chronic hypoparathyroidism a standardized interview as well as blood sampling and examinations such as echocardiography and renal ultrasound are performed.",[231,26,232,233,234],"Comorbidities and Coexisting Conditions","Hypocalcemia","Hypercalcemia","Quality of Life","2022-11-02",{"date":237,"type":36},"2022-11-08",{"date":239,"type":36},"2017-10-18",{"date":241,"type":22},"2032-01-01",{"name":243,"class":43},"University of Wuerzburg",{"id":245,"slug":246,"hasResults":11,"nctId":247,"briefTitle":248,"officialTitle":249,"acronym":250,"eligibilityCriteria":251,"healthyVolunteers":115,"sex":17,"minAge":18,"maxAge":252,"enrollmentInfo":253,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":255,"conditions":256,"keywords":260,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":264,"lastUpdatePostDateStruct":265,"startDateStruct":267,"completionDateStruct":269,"leadSponsor":271,"locationsCount":4},"100473647","role-of-empathy-in-curative-treatment-outcomes-of-non-metastatic-colorectal-cancer-100473647","NCT05447611","Role of Empathy in Curative Treatment Outcomes of Non-metastatic Colorectal Cancer.","Role of Empathy in the Outcome of Curative Treatment of Non-metastatic Colorectal Cancer. Prospective Multicenter Longitudinal Study in Two Departments Covered by the Calvados Cancer Registry.","EMPACOL","Inclusion Criteria:\n\nPatients aged 18 to 75 years, French-speaking, affiliated to a social security system, having received informed information and not having expressed an unfavorable opinion to participate; carriers of non-metastatic and uncomplicated CRC (without occlusion\u002F perforation\u002Fbleeding), requiring elective therapeutic management. The included patients have a cognitive state capable of understanding and completing the questionnaires (autonomous completion).\n\nExclusion Criteria:\n\nPatients who were minors or older than 80 years, residing in a department outside Calvados or Manche, presenting a CRC other than adenocarcinoma and all metastatic forms or requiring emergency surgery (perforation, hemorrhage, occlusion), exclusive endoscopic treatment, or a missed-CRC discovered after surgery for non-oncological indications.\n\nPatients with another neoplastic disease under treatment and\u002For evolving, patients with a history of inflammatory bowel disease (Crohn's disease, ulcerative colitis) and\u002For hereditary disease predisposing to CRC (Lynch syndrome, familial polyposis) or with severe cognitive impairment preventing proper comprehension of the questionnaires. Pregnant women will be excluded.","80 Years",{"count":254,"type":22},250,"The aim of project EMPACOL will be to investigate, while taking into consideration the clinical factors known and well described in the literature, among the non-clinical factors, in particular, patient-healthcare personnel (HCP) relationship, a link between HCP's empathy perceived by the patient, and the results of the curative treatment of non-metastatic colorectal cancer, throughout the patient's care.",[257,258,259,26,234],"Non-metastatic Colorectal Cancer","Empathy","Morbidity",[261,262,263],"colorectal cancer","empathy","outcomes","2022-07-06",{"date":266,"type":36},"2022-07-07",{"date":268,"type":22},"2022-09",{"date":270,"type":22},"2029-09",{"name":272,"class":43},"University Hospital, Caen"]